HC Wainwright Forecasts Reduced Earnings for Legend Biotech

Legend Biotech Co. (NASDAQ:LEGN) – HC Wainwright decreased their Q2 2025 earnings estimates for shares of Legend Biotech in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of $0.24 per share for the quarter, down from their prior forecast of $0.28. HC Wainwright currently has a “Buy” rating and a $73.00 target price on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Legend Biotech’s Q4 2025 earnings at $0.12 EPS.

Legend Biotech (NASDAQ:LEGN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.22. The business had revenue of $160.20 million for the quarter, compared to the consensus estimate of $143.91 million. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%. The company’s quarterly revenue was up 66.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.17) earnings per share.

A number of other research analysts have also recently weighed in on LEGN. Royal Bank of Canada reiterated an “outperform” rating and set a $86.00 price objective on shares of Legend Biotech in a research report on Tuesday, October 29th. Scotiabank increased their price objective on shares of Legend Biotech from $70.00 to $76.00 and gave the stock a “sector outperform” rating in a research report on Monday, August 12th. Finally, Redburn Atlantic began coverage on Legend Biotech in a research report on Tuesday, October 8th. They set a “buy” rating and a $86.00 target price for the company. Thirteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Legend Biotech has a consensus rating of “Buy” and an average price target of $81.46.

Legend Biotech Stock Performance

NASDAQ:LEGN opened at $38.19 on Thursday. The firm has a market capitalization of $6.96 billion, a PE ratio of -40.20 and a beta of 0.11. The stock’s fifty day moving average is $46.01 and its 200 day moving average is $48.23. Legend Biotech has a fifty-two week low of $38.02 and a fifty-two week high of $70.13. The company has a debt-to-equity ratio of 0.27, a quick ratio of 4.78 and a current ratio of 4.98.

Institutional Investors Weigh In On Legend Biotech

A number of institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC lifted its stake in Legend Biotech by 4.0% in the third quarter. FMR LLC now owns 18,330,219 shares of the company’s stock worth $893,232,000 after acquiring an additional 708,620 shares during the period. RA Capital Management L.P. lifted its position in shares of Legend Biotech by 9.5% in the 1st quarter. RA Capital Management L.P. now owns 6,861,097 shares of the company’s stock worth $384,839,000 after purchasing an additional 596,390 shares during the period. Westfield Capital Management Co. LP boosted its stake in shares of Legend Biotech by 26.1% during the first quarter. Westfield Capital Management Co. LP now owns 2,239,774 shares of the company’s stock valued at $125,629,000 after purchasing an additional 463,527 shares in the last quarter. Capital International Investors increased its holdings in Legend Biotech by 19.5% during the first quarter. Capital International Investors now owns 2,181,074 shares of the company’s stock valued at $122,336,000 after buying an additional 356,387 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its holdings in Legend Biotech by 16.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,275,158 shares of the company’s stock valued at $110,868,000 after buying an additional 314,449 shares during the period. 70.89% of the stock is owned by institutional investors.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).